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Abstract: There is a mechanistic link between the gut-derived metabolite trimethylamine-N-oxide
(TMAO) and obesity-related diseases, suggesting that the TMAO pathway may also be linked to the
pathogenesis of obesity. The Visceral Adiposity Index (VAI), a gender-specific indicator of adipose
dysfunction, and the Fatty Liver Index (FLI), a predictor of non-alcoholic fatty liver disease (NAFLD),
are early predictors of metabolic syndrome (MetS). In this cross-sectional observational study, we
investigated TMAO levels in adults stratified according to Body Mass Index (BMI) and the association
of TMAO with VAI and FLI. One hundred and thirty-seven adult subjects (59 males; 21–56 years) were
enrolled. TMAO levels were detected using HPLC/MS analysis. Homeostatic Model Assessment
of Insulin Resistance (HoMA-IR), VAI and FLI were included as cardio-metabolic indices. TMAO
levels increased along with BMI and were positively associated with VAI and FLI, independently,
on common potential covariates. The most sensitive and specific cut-offs for circulating levels of
TMAO to predict the presence of NAFLD-FLI and MetS were ≥8.02 µM and ≥8.74 µM, respectively.
These findings allow us to hypothesize a role of TMAO as an early biomarker of adipose dysfunction
and NAFLD-FLI in all borderline conditions in which overt MetS is not present, and suggest that a
specific cut-off of TMAO might help in identifying subjects at high risk of NAFLD.
Keywords: trimethylamine N-oxide (TMAO); obesity; visceral adiposity index (VAI); fatty liver index
(FLI); metabolic syndrome (MetS)
1. Introduction
TMAO is a small, organic, gut microbiota-derived metabolite, which is emerging as a
new potentially important cause of increased atherosclerosis and cardiovascular risk [1–3].
Circulating levels of TMAO increase after the gut microbial metabolism of dietary L-carnitine and
phosphatidylcholine-rich foods, including red meat, eggs, dairy products, which are common nutrients
of the Western diet. Very recently we reported a novel association between circulating levels of TMAO
and the Mediterranean diet in healthy normal-weight adults, with a clear gender difference in this
association [4]. The metabolic pathway of TMAO includes the digestion of these amines from gut
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microbiota with the production of trimethylamine (TMA), which is then converted to TMAO via
flavin-monooxygenase-3 (FMO3) in the liver [5,6]. The interplay between dietary composition, gut
microbiota and microbe-generated metabolites has been intensely investigated [7,8].
Several studies have shown a mechanistic link between TMAO, inflammatory pathways [9]
atherosclerosis, type 2 diabetes mellitus (T2DM), and cardiovascular diseases (CVD) [1–3,6,10,11].
Namely, circulating levels of TMAO and its metabolites (choline and betaine) are associated with
atherosclerosis risks in both humans and mice [1]. Among the pro-atherosclerotic mechanisms
proposed for TMAO there are the inhibition of the reverse cholesterol transport, although this effect
was reported in animal studies only [6], and the enhancement of human platelet hyperresponsiveness
and thrombosis potential [10]. A systematic review and meta-analysis by Schiattarella et al. [2]
demonstrated that in humans there is a positive dose-dependent association between circulating levels
of TMAO and increased cardiovascular risk and mortality [2]. Nevertheless, in this metanalysis, the
population samples were not divided according the BMI classes. More recently, Kanitsoraphan et al. [3]
reported that in patients with T2DM higher circulating levels of TMAO were significantly associated
with higher overall mortality by 2.07- to 2.7-fold, also after adjustment for BMI [3]. Recently, the strong
association between gut microbiota and either obesity and obesity-related diseases in humans on the
one hand, and the association between the TMAO pathway and cardio-metabolic diseases on the other,
suggested that the TMAO pathway may be also mechanistically linked to the pathogenesis of obesity.
Schugar et al. [11] reported that plasma TMAO levels were linked to with obesity traits in the different
inbred strains of mice receiving a high-fat diet and suggested that the TMAO-generating pathway is
linked to obesity and energy metabolism [11], although scientific evidence to support this association
in humans has not yet been provided. Only Randrianarisoa et al. [12] reported that TMAO correlated
positively with BMI, insulin resistance, visceral fat mass, and liver fat content [12]. In addition, Chen et
al. [13] showed positive associations of the circulating TMAO levels and two of its nutrient precursors,
choline, and betaine, with the presence and severity of NAFLD, the hepatic manifestation of the
MetS [14], in a large sample of hospital- and community-based Chinese adults [13].
Nevertheless, controversy remains over the exact role of TMAO in the pathogenesis of MetS,
a constellation of cardio-metabolic risk factors, including central obesity, hypertriglyceridemia,
low high-density lipoprotein (HDL) cholesterol, hyperglycemia, and hypertension [15], which
predispose T2DM and CVD [16], according to the definition of nascent MetS [17]. Very recently,
a clinical study investigating several biogenic amines in urine, including TMAO in a sample of
patients with MetS showed that these subjects presented higher levels of TMAO compared with their
counterparts without MetS [18]. In addition, a further study investigating unselected white patients
undergoing coronary angiography for the evaluation of suspected coronary artery disease showed a
positive correlation between TMAO and MetS [19]. However, this association was lost after adjusting
for impaired kidney function and poor metabolic control in this population sample.
On the other hand, this association was not found in a sample of patients with nascent MetS
(without CVD or T2DM), but not with the commonly used surrogate index of insulin resistance, i.e.,
the HoMA-IR [9]. Again, in these recent studies, the population samples were not divided according
to BMI classes.
The VAI, a gender-specific indicator of adipose distribution and dysfunction [20], and the FLI, an
accurate predictor of the NAFLD [21], are two surrogate indices of cardio-metabolic risk and are linked
to the inflammatory pathways [22,23]. Both indices are based on simple anthropometric and metabolic
parameters, and are strictly correlated with MetS, representing early predictors of MetS [20,24]. VAI
has been counted as an effective marker to assess insulin resistance and metabolic disturbances that
contribute to CVD in primary-care non-obese subjects, with specific cut-off values depending on the
population of interest [20]. Also, FLI has been proposed as a marker of insulin resistance [21] and
recently the clinical utility of FLI as a predictor of incident T2DM has been reported [25]. As three
of the variables making up VAI (waist circumference (WC), plasma triglycerides (TG), and HDL
cholesterol) and FLI (BMI, WC, and TG) are used as continuous variables, and while they are
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dichotomically expressed in the criteria for MetS, VAI and FLI might represent useful indicators
of early cardio-metabolic risk in all borderline conditions in which overt MetS is not present [22].
Considering the lack of evidence in humans of a progressive increase of TMAO levels across BMI
classes and to gain further insight into the levels of TMAO in the setting of obesity, in this study we
aimed to investigate the circulating levels of TMAO in a sample of the adult population stratified
according to BMI. In addition, considering the still controversial role of TMAO in the pathogenesis of
MetS and the predictive value of VAI and FLI as easy and early indicators of MetS, we investigated the
association of circulating levels of TMAO with VAI and FLI and hypothesized that this association could
serve as a biological marker of early metabolic derangement in subjects with overweight and obesity.
2. Materials and Methods
2.1. Design and Setting
This is a cross-sectional observational study carried out at the Department of Clinical Medicine and
Surgery, Unit of Endocrinology, University Federico II, Naples (Italy), from January 2017 to August 2018.
The work has been carried out in accordance with the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans, and it has been approved by the Ethical
Committee of the University of Naples “Federico II” Medical School (n. 173/16). The purpose of the
protocol was explained to all the study participants, and written informed consent was obtained. This
trial was registered at http://register.clinicaltrials.gov/. Unique identifier: NCT03060811.
2.2. Population Study
Recruitment strategies included a sample of 330 adult Caucasians subjects (20–63 years) of
both genders consecutively enrolled among patients of our outpatient clinic, hospital volunteers,
and employees from the same geographical area around Naples, Italy). All female subjects were
non-pregnant and non-lactating. A full medical history, including drug use, was collected.
To increase the homogeneity of the subject sample, we included only adults of both genders with
the following criteria of exclusion:
• Impaired renal function (normal values: estimated glomerular filtration rate≥ 90 mL/min/1.73 m2
calculated by chronic kidney disease epidemiology collaboration equation; CKD EPI) (15 patients)
• Presence of T2DM (defined by criteria of the American Diabetes Association as follows: basal
plasma glucose level ≥ 126 mg/dL on two occasions, or glycated hemoglobin (HbA1c) ≥ 6.5%
(≥48 mmol/mol) on two occasions, or both at the same time (35 patients). Participants on
antidiabetic medication were considered to have T2DM [26].
• Clinical atherosclerosis (coronary artery disease, peripheral vascular disease, CVD) (41 patients)
• Current therapy with anti-inflammatory drugs, statins and other hypolipidemic agents
(34 patients);
• User of antibiotics or probiotics within 2 months of recruitment (19 subjects);
• Specific nutritional regimens, including vegan or vegetarian diets (eight subjects);
• Vitamin/mineral or antioxidant supplementation (34 subjects);
• Alcohol abuse according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-V
diagnostic criteria (eleven subjects);
The flow chart of the study subjects is shown in Figure 1.
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Figure 1. Flow chart of the studied subjects.
2.3. Lifestyle Habits
Lifestyle habits, including smoking and physical activity level, have been investigated as follows:
subjects smoking at least one cigarette per day were considered current smokers, while former smokers
were the subjects who stopped smoking at least one year before the interview. Remaining participants
were defined as non-smokers. Physical activity levels were expressed according to whether the
participant habitually engaged at least 30 min/day of aerobic exercise (YES/NO).
2.4. Anthropometric Measurements and Blood Pressure
Measurements were p rformed between 8 and 12 a.m. All subjects were measured after an
overnight fast. The measurements were made in a standard way by the same operator (a nutritionist
experienced in providing nutritional assessment and body composition). At the beginning of the study,
all anthropometric measurements were taken with subjects wearing only light clothes and without
shoes. In each subject, weight and height were measured to calculate the BMI [weight (kg) divided
by height squared (m2), kg/m2]. Height was measured to the nearest 0.5 cm using a wall-mounted
stadiometer (Seca 711; Seca, Hamburg, Germany). Body weight was determined to the nearest 0.1
kg using a calibrated balance beam scale (Seca 711; Seca, Hamburg, Germany). BMI was classified
according to the World Health Organization (WHO)’s criteria with normal weight: 18.5–24.9 kg/m2;
overweight, 25.0–29.9 kg/m2; grade I obesity, 30.0–34.9 kg/m2; grade II obesity, 35.0–39.9 kg/m2;
grade III obesity ≥ 40.0 kg/m2 [27]. WC was measured to the closest 0.1 cm using a non-stretchable
measuring tape at the natural indentation or at a midway level between the lower edge of the rib cage
and the iliac crest if no natural indentation was visible, as per the National Center for Health Statistics
(NCHS) [28]. In all subjects Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were
measured three times, two min apart, with a random zero sphygmomanometer (Gelman Hawksley
Ltd., Sussex, UK) after the subject had been sitting for at least 10 min. The average of the second and
third reading was recorded.
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2.5. Determination of Circulating Levels of TMAO
TMAO serum levels were measured in samples stored at −80 ◦C. A previous study indicated
that, under these conditions, TMAO is stable for several years [29]. The quantification of circulating
TMAO levels has been performed using the method described by Beale and Airs [30], and reported
in our previous study [4], with slight modifications. Briefly, serum proteins were precipitated with
methanol (serum:methanol, 1:2, v/v); samples were vortex-mixed for 2 min, centrifuged at 14,000 g
for 10 min (4 ◦C) [31] and supernatants were collected and analyzed by High-Performance Liquid
Chromatography-Mass Spectrometry (HPLC-MS) method. Both HPLC-MS conditions and method
optimization were performed in accordance with Beale and Airs [30]. The HPLC system Jasco Extrema
LC-4000 system (Jasco Inc., Easton, MD, USA) was coupled to a single quadrupole mass spectrometer
(Advion ExpressIonL CMS, Advion Inc., Ithaca, NY, USA) equipped with an Electrospray ionization
(ESI) source, operating in positive ion mode. The chromatographic separation was performed with a
Luna HILIC column (150 × 3 mm, 5 µm particles) in combination with a guard column (HILIC), both
supplied by Phenomenex (Torrance, CA, USA).
2.6. Assay Methods
Samples were collected in the morning between 8 and 10 a.m., after an overnight fast of at least 8 h
and stored at −80 ◦C until being processed. All biochemical analyses including fasting plasma glucose,
total cholesterol, fasting plasma TG, Alanine Transaminase (ALT), Aspartate Aminotransferase (AST),
and γ-Glutamyltransferase (γGT) were performed with a Roche Modular Analytics System in the
Central Biochemistry Laboratory of our Institution. Low-Density Lipoprotein (LDL) cholesterol and
HDL cholesterol were determined by a direct method (homogeneous enzymatic assay for the direct
quantitative determination of LDL and HDL cholesterol). Fasting insulin levels were measured by a
solid-phase chemiluminescent enzyme immunoassay using commercially available kits (Immunolite
Diagnostic Products Co., Los Angeles, CA, USA). The intra-assay coefficients of variations (CV) was
<5.5%, as already widely reported in our previous studies [32–36].
2.7. Cardio-Metabolic Indices
HoMA-IR was calculated according to Matthews et al. [37]. A value of HoMA-IR >2.5 was used
as cut-off of insulin resistance. VAI score has been calculated by the following sex-specific formula,
with TG levels expressed in mmol/L and HDL levels expressed in mmol/L:
Males: VAI = [WC/39.68 + (1.88 × BMI)] × (TG/1.03) × (1.31/HDL), (1)
Females: VAI = [WC/36.58 + (1.89 × BMI)] × (TG/0.81) × (1.52/HDL), (2)
Age-specific VAI cut-off values were used according to Amato et al. [22,38]. In detail, cut-offs in
subjects aged ≤30, 31–42, 43–52, and 53–66 years old were 2.52, 2.23, 1.92, 1.93, respectively [22,38].
FLI was calculated with the formula:
[FLI = eL/(1 + eL) × 100, L = 0.953 × loge triglycerides + 0.139 × BMI
+ 0.718 × logeγGT + 0.053 × WC−15.745]. (3)
FLI of 30 was considered as the cut-off value based on Bedogni’s criterion [21].
2.8. Criteria to Define MetS
According to the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III
definition, MetS is present if three or more of the following five criteria are met: WC ≥ 102 cm (men)
or 88 cm (women), blood pressure ≥ 130/85 mmHg, fasting TG level ≥ 150 mg/dL, fasting HDL
cholesterol level ≤ 40 mg/dL (men) or ≤50 mg/dL (women), and fasting glucose ≥ 100 mg/dL [39].
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2.9. Dietary Assessment
As has been already widely reported in the literature [34–36,40], data were obtained during
a face-to-face interview between the patient and a qualified nutritionist. Specifically, the dietary
interview allowed the quantification of foods and drinks by using a photographic food atlas (≈1000
photographs) of known portion sizes to ensure accurate completion of the records [41]. On day
1, the diary nutritionists were trained to standardized protocols and provided participants with
instructions on how to complete the diary at the health check, and asked participants to recall the
previous day’s intake. Participants prospectively completed the remaining 6 days and returned the
records to the nutritionist [42]. Data were processed using a commercial software (Terapia Alimentare
Dietosystem® DS-Medica, http://www.dsmedica.info). Considering quantities of foods consumed,
the software can calculate the total energy intake, expressed in kilocalories (kcal).
2.10. Statistical Analysis
The data distribution was evaluated by Kolmogorov-Smirnov test and the abnormal data were
normalized by logarithm. Skewed variables were back-transformed for presentation in tables and
figures. Results are expressed as mean ± standard deviation (SD). The chi square (χ2) test was used to
determine the significance of differences in frequency distribution of smoking habit, physical activity,
and presence/absence of MetS. Differences according to gender, lifestyle habits, cardio-metabolic
indices, and MetS were analyzed by Student’s unpaired t-test, while the differences among the classes
of BMI were analyzed by ANOVA followed by the Bonferroni post-hoc test. The correlations between
study variables were performed using Pearson r correlation coefficients and were estimated after
adjusting for gender, BMI, smoking, physical activity, and total energy intake. Proportional Odds
Ratio (OR) models, 95% Interval Confidence (IC), and R2 were performed to assess the association
between gender, lifestyle habits, classes of BMI, cardio-metabolic indices, and MetS. In addition,
two multiple linear regression analysis models (stepwise method), expressed as R2, Beta (β), and t,
with circulating levels of TMAO as dependent variables were used to estimate the predictive value
of: (a) cardio-metabolic indices; and (b) FLI and MetS. Receiver operator characteristic (ROC) curve
analysis was performed to determine sensitivity and specificity, area under the curve (AUC), and
IC, as well as cut-off values of circulating levels of TMAO in detecting FLI and MetS. Test AUC for
ROC analysis was also performed. We wanted to show that AUC being 0.943 for a particular test
is significant from the null hypothesis value 0.5 (meaning no discriminating power), so we entered
0.943 for AUC ROC and 0.5 for null hypothesis values. For α level we selected 0.05 type I error and
for β level we selected 0.20 type II error. In these analyses, we entered only those variables that had
a p-value < 0.05 in the univariate analysis (partial correlation). To avoid multicollinearity, variables
with a variance inflation factor (VIF) >10 were excluded. Values ≤0.05% were considered statistically
significant. Data were stored and analyzed using the MedCalc® package (Version 12.3.0 1993–2012
MedCalc Software bvba—MedCalc Software, Mariakerke, Belgium).
3. Results
The study population consisted of 137 participants, 59 males and 78 females, aged 21–56 years.
Current smokers were 49.6% (68 subjects). A moderate-intensity aerobic activity at least 5 days per
week was reported in 42.3% (58 subjects). BMIs ranged from 19.6 to 58.8 kg/m2. Median values of
HoMA-IR, VAI and FLI were 1.95 (0.1–15.16), 1.89 (0.60–13.85) and 75.30 (3.40–100.0), respectively. In
particular, 64 subjects (46.7%) had HoMA-IR values higher than the cut-off. VAI was higher than sex-
and age-specific cut-offs in 43.8% (60 subjects) and 59.9% (82 subjects) presented FLI values above the
cut-off. MetS was present in 53 participants (38.7%).
In Table 1 we report the lifestyle habits, anthropometric measurements, blood pressure, metabolic
profile, and cardio-metabolic indices in the total population grouped based on BMI categories. As
shown in Table 1, no differences were observed in age (p = 0.292), while subjects with overweight
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and obesity exhibited statistical differences in all parameters compared with normal-weight subjects
(p < 0.001). In particular, circulating levels of TMAO increased with the BMI classes, with the highest
TMAO values in the class III obesity.
Table 1. Lifestyle habits, anthropometric characteristics, blood pressure, metabolic profile,
cardio-metabolic indices, and total energy intake of participants grouped based on BMI categories.
Parameters Normal Weightn = 34; 24.8%
Over Weight
n = 29; 21.2%
Grade I Obesity
n = 21; 15.3%
Grade II
Obesity
n = 15; 10.9%
Grade III
Obesity
n = 38; 27.7%
p-value
Lifestyle Habits
Age (years) 35.71 ± 8.48 38.14 ± 7.58 38.24 ± 5.89 35.80 ± 8.20 35.00 ± 6.82 0.292
Smoking (yes) 16, 47.1% 19, 65.5% 4, 19.0% 2, 13.3% 22, 10.5% χ
2 = 19.21,
p < 0.001
Physical activity (yes) 22, 64.7% 11, 37.9% 3, 14.3% 5, 33.3% 4, 10.5% χ
2 = 27.85,
p < 0.001
Anthropometric
measurement
BMI (kg/m2) 23.01 ± 1.49 27.32 ± 1.43 32.41 ± 1.37 37.48 ± 1.56 46.99 ± 5.16 <0.001
WC (cm) 85.12 ± 10.13 94.30 ± 12.38 109.65 ± 8.14 118.81 ± 13.40 139.47 ± 15.15 <0.001
Blood pressure
SBP (mmHg) 115.44 ± 8.01 121.21 ± 10.90 129.52 ± 10.83 131.00 ± 16.38 133.68 ± 11.79 <0.001
DBP (mmHg) 71.33 ± 6.07 75.68 ± 7.41 81.67 ± 6.77 86.33 ± 11.25 89.61 ± 9.25 <0.001
Metabolic profile
Circulating levels of
TMAO (µM) 3.62 ± 2.37 8.23 ± 0.67 9.03 ± 0.97 9.89 ± 0.85 11.53 ± 0.96 <0.001
Fasting Glucose (mg/dL) 83.65 ± 10.25 93.17 ± 13.10 96.47 ± 12.11 97.73 ± 11.00 121.87 ± 10.91 <0.001
Insulin (µU/mL) 2.66 ± 1.23 7.01 ± 5.35 10.69 ± 5.83 14.85 ± 9.65 31.29 ± 8.87 <0.001
Total cholesterol (mg/dL) 146.8 ± 20.28 176.69 ± 29.17 170.76 ± 20.85 206.87 ± 39.57 221.37 ± 33.58 <0.001
HDL cholesterol (mg/dL) 57.59 ± 7.53 50.21 ± 8.19 41.95 ± 13.28 39.60 ± 10.60 37.05 ± 9.42 <0.001
LDL cholesterol (mg/dL) 69.92 ± 23.15 101.43 ± 30.05 103.37 ± 16.67 134.49 ± 41.49 150.17 ± 38.54 <0.001
Triglycerides (mg/dL) 96.71 ± 26.96 125.24 ± 28.30 155.52 ± 65.23 163.87 ± 33.78 170.74 ± 70.88 <0.001
ALT (U/L) 23.26 ± 6.87 24.89 ± 9.06 38.14 ± 12.16 40.73 ± 17.87 41.39 ± 22.49 <0.001
AST (U/L) 20.44 ± 5.57 26.58 ± 6.67 36.83 ± 18.25 39.07 ± 14.10 41.00 ± 20.12 <0.001
γGT (U/L) 25.64 ± 6.62 26.52 ± 12.48 42.42 ± 19.71 44.47 ± 19.65 49.53 ± 27.20 <0.001
Cardio-metabolic indices
HoMA-IR 0.55 ± 0.28 1.49 ± 0.96 2.51 ± 1.32 3.55 ± 2.31 9.52 ± 3.13 <0.001
VAI 1.28 ± 0.54 2.09 ± 1.27 3.42 ± 2.91 3.55 ± 1.97 3.77 ± 2.18 <0.001
FLI 19.89 ± 12.37 43.70 ± 21.36 79.39 ± 10.26 90.98 ± 6.97 98.36 ± 2.30 <0.001
Metabolic Syndrome
MetS (number parameter) 0.18 ± 0.52 1.24 ± 1.02 2.33 ± 1.06 2.67 ± 1.40 3.68 ± 1.07 <0.001
MetS (presence) 0, 0 4, 13.8% 9, 42.9% 9, 60% 31, 81.6% χ
2 = 61.53,
p < 0.001
Nutritional parameters
Total energy intake (kcal) 2084.79 ± 304.05 2249.14 ± 433.86 2423.33 ± 211.27 2658.67 ± 244.80 2966.45 ± 365.69 <0.001
A p-value in bold type denotes a significant difference (p < 0.05).
Circulating levels of TMAO according to gender, lifestyle habits, and cut-off of the
cardio-metabolic indices are reported in Table 2. As reported in Table 2, circulating levels of TMAO
were significantly higher in males (p = 0.015), among current smokers or physically inactive individuals
(p < 0.001), and in subjects with cardio-metabolic indices higher than cut-offs (p < 0.001). In addition,
circulating levels of TMAO were significantly higher in presence of MetS (p < 0.001).
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Table 2. Circulating levels of TMAO in the study population according to gender, lifestyle habits,
cardio-metabolic indices, and MetS.
Parameters Circulating Levels ofTMAO (µM) p-value
Gender Males (n 59) 9.11 ± 3.09 0.015
Females (n 78) 7.70 ± 3.28
Smoking Yes (n 68) 9.38 ± 2.63 <0.001
No (n 69) 7.24 ± 3.49
Physical activity Yes (n 58) 6.41 ± 3.52 <0.001
No (n 79) 9.69 ± 2.21
HoMA-IR > cut-off (n 64) 10.53 ± 1.62 <0.001
< cut-off (n 73) 6.36 ± 3.01
VAI > cut-off (n 60) 10.08 ± 2.13 <0.001
< cut-off (n 77) 6.92 ± 3.33
FLI > cut-off (n 82) 10.24 ± 1.56 <0.001
< cut-off (n 55) 5.42 ± 3.00
MetS (parameters)
WC Yes (n 87) 9.88 ± 2.06 <0.001
No (n 50) 5.56 ± 3.18
SBP/DBP Yes (n 37) 10.49 ± 1.72 <0.001
No (n 100) 7.50 ± 3.33
Fasting Glucose Yes (n 43) 11.29 ± 1.22 <0.001
No (n 94) 6.94 ± 2.98
HDL cholesterol Yes (n 59) 10.13 ± 2.09 <0.001
No (n 78) 6.93 ± 3.33
Triglycerides Yes (n 45) 10.28 ± 2.20 <0.001
No (n 92) 7.34 ± 3.27
MetS (presence/absence) Yes (n 53) 10.65 ± 1.62 <0.001
No (n 84) 6.82 ± 3.17
A p-value in bold type denotes a significant difference (p < 0.05).
Correlation Analysis
The correlations between circulating levels of TMAO, age, components of the MetS, metabolic
profile, cardio-metabolic indices, are summarized in Table 3. Apart from the age, circulating levels of
TMAO show significant correlations with all metabolic parameters. After adjusting for gender, BMI,
smoking, physical activity, and total energy intake, correlations with almost all the components of
MetS and cardio-metabolic indices were still evident, as shown in Table 3.
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Table 3. Correlations among circulating levels of TMAO with age, anthropometric characteristics,
blood pressure, metabolic profile, cardio-metabolic indices, and nutritional parameter.
Parameters
Circulating Levels of TMAO (µM) Circulating Levels of TMAO (µM)
Simple Correlation After Adjusting
r p-value r p-value
Age (years) 0.103 0.232 0.169 0.054
Anthropometric
measurements
BMI (kg/m2) 0.737 <0.001 - -
WC (cm) 0.670 <0.001 −0.055 0.538
Blood pressure
SBP (mmHg) 0.600 <0.001 0.273 0.002
DBP (mmHg) 0.532 <0.001 0.149 0.091
Metabolic profile
Fasting Glucose (mg/dL) 0.656 <0.001 0.034 0.700
Insulin (µU/mL) 0.668 <0.001 0.202 0.021
Total cholesterol (mg/dL) 0.628 <0.001 0.236 0.007
HDL cholesterol (mg/dL) −0.568 <0.001 −0.180 0.041
LDL cholesterol (mg/dL) 0.663 <0.001 0.356 <0.001
Triglycerides (mg/dL) 0.535 <0.001 0.224 0.010
ALT (U/L) 0.376 0.001 0.065 0.461
AST (U/L) 0.506 <0.001 0.176 0.046
γGT (U/L) 0.396 0.001 0.086 0.333
Cardio-metabolic indices
HoMA-IR 0.699 <0.001 0.211 0.016
VAI 0.549 <0.001 0.255 0.003
FLI 0.820 <0.001 0.604 <0.001
Nutritional parameter
Total energy intake (kcal) 0.592 <0.001 - -
A p-value in bold type denotes a significant difference (p < 0.05).
The results of bivariate proportional OR model performed to assess the association of circulating
levels of TMAO with quantitative variables are reported in Table 4. The highest circulating levels
of TMAO are significantly associated with the severity of obesity (OR 9.59; p < 0.001), and insulin
resistance (OR 2.82; p < 0.001). Moreover, the highest levels of TMAO are associated with the highest
levels of VAI (OR 1.58; p < 0.001) and FLI (OR 4.31; p < 0.001), presence of MetS (OR 2.36; p < 0.001)
and of all components of the MetS.
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Table 4. Bivariate proportional odds ratio model to assess the association between circulating levels of
TMAO and gender, lifestyle habits, cardio-metabolic indices, and MetS.
Parameters Circulating Levels of TMAO (µM)
OR p-value 95% IC R2
Gender 1.15 0.015 1.029–1.295 0.047
Smoking 1.26 0.001 1.110–1.423 0.108
Physical activity 0.67 <0.001 0.576–0.788 0.240
BMI categories
Normal weight 0.05 0.001 0.009–0.297 0.604
Overweight 0.27 <0.001 0.011–1.121 0.209
Grade I obesity 0.18 <0.001 0.010–0.099 0.237
Grade II obesity 1.25 <0.001 0.995–1.565 0.033
Grade III obesity 9.59 <0.001 3.946–23.344 0.561
HoMA-IR 2.82 <0.001 1.937–4.116 0.458
VAI 1.58 <0.001 1.308–1.912 0.248
FLI 4.31 <0.001 2.353–7.874 0.536
MetS (single parameters)
WC 1.88 <0.001 1.490–2.375 0.378
SBP/DBP 1.64 <0.001 1.304–2.065 0.201
Fasting Glucose 5.84 <0.001 3.161–10.804 0.538
HDL cholesterol 1.61 <0.001 1.320–1.953 0.254
Triglycerides 1.57 0.001 1.278–1.919 0.205
MetS (presence/absence) 2.36 <0.001 1.727–3.227 0.389
A p-value in bold type denotes a significant difference (p < 0.05).
To compare the relative predictive power of the cardio-metabolic indices associated with the
circulating levels of TMAO, we performed a multiple linear regression analysis using a model that
included as HoMA-IR, VAI, and FLI. Using this model, FLI entered at the first step (p < 0.001), while
HoMA-IR, VAI were excluded. To compare the relative predictive power of FLI and number of
components of MetS associated with the circulating levels of TMAO, we performed a second multiple
linear regression analysis model. Using this second model, FLI entered at the first step (p < 0.001),
while the number of components of MetS were excluded. Results were reported in Table 5.
Table 5. Multiple regression analysis models (stepwise method) with the circulating levels of TMAO as
dependent variable to estimate the predictive value of: (a) cardio-metabolic indices; (b) FLI and MetS.
Parameters Multiple Regression Analysis
Model 1 R2 β t p-value
FLI 0.672 0.820 16.63 <0.001
Variables excluded: HoMA-IR and VAI
Model 2
FLI 0.469 0.685 9.2 <0.001
Variables excluded: MetS
A p-value in bold type denotes a significant difference (p < 0.05).
A ROC analysis was then performed to determine the cut-off values of circulating levels of TMAO
predictive of MetS and FLI. In particular, circulating levels of TMAO ≥8.74 µM (p < 0.001, AUC 0.876,
standard error 0.029, 95% CI 0.808 to 0.926; Figure 2a), and circulating levels of TMAO ≥8.02 µM
(p < 0.001, AUC 0.943, standard error 0.018, 95% CI 0.890 to 0.975; Figure 2b), could serve as thresholds
for significantly increased risk of the presence of MetS and NAFLD, respectively.
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4. Discussion
In this cross-section l observational study, we evaluate th circulating levels of TMAO in a
sample of adult population stratified according to categories of BMI. In addition, we investigated the
association among circulating levels of TMAO and cardio-metabolic indices. The classification of the
study population according to the BMI demonstrated that circulating levels of TMAO increased along
with BMI. To the best of our knowledge, this is the first study that reported statistical differences in the
circulating levels of TMAO across classes of BMI. Moreover, we confirmed the presence of a positive
association of circulating levels of TMAO with MetS, the increasing number of its components, and
HoMA-IR. Finally, a novel association was also reported among the circulating levels of TMAO and
VAI and FLI, two surrogate indices of cardio-metabolic risk and early indicators of MetS, independently
on common potential covariates.
There is a paucity of literature that has studied the relationship between TMAO and adiposity.
A recent experimental study reported that both antisense oligonucleotide-mediated knockdown and
genetic deletion of the TMAO-producing enzyme FMO3 protected mice against high-fat diet-induced
obesity, thus highlighting a role of the gut microbe-driven TMA/FMO3/TMAO pathway in affecting
specific transcriptional reprogramming in white adipocytes [11]. Of interest, in this study circulating
levels of TMAO were positively associated with body weight, fat mass, mesenteric adiposity, and
subcutaneous adiposity across the different mice-inbred strains; in addition, in cohorts of overweight
or obese subjects with metabolic traits and different ethnicity the expression of FMO3 in liver biopsies
was positively correlated with BMI and waist-to-hip ratio, and negatively correlated with the Matsuda
Index, a measure of insulin sensitivity [11]. Consistent with these data, the findings of the present study
show that there is a clear positive association of circulating TMAO levels and classes of BMI. Thus,
besides its role as a risk factor for CVD and adverse event in risks subjects, emerging evidence suggests
that gut microbiota-derived TMAO might represent per se a key environmental factor contributing to
obesity and obesity-associated disorders.
VAI is a surrogate of adipocyte dysfunction independently correlated with insulin sensitivity, and
cardio-metabolic risk in primary-care non-obese subjects [20]. In particular, VAI was proposed as a
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useful tool for the early detection of a condition of insulin resistance and cardio-metabolic risk before it
develops into an overt MetS [38]. FLI is a surrogate marker of a fatty liver considered a screening tool
to identify NAFLD, recognized as the liver manifestation of MetS, in subjects with insulin resistance
and cardio-metabolic risk factors where ultrasound is unavailable [43]. In our population sample
there was a positive association between circulating levels of TMAO and both indices. Of interest,
the association of the circulating levels of TMAO with VAI and FLI was also shown independently
on potential covariates, such as gender, BMI, smoking status, physical activity, and energy intake. In
addition, among the cardio-metabolic indices included in this study, FLI, which incorporates BMI, WC,
TG, and liver function, was a better predictor of TMAO variability than MetS per se. This finding was
in line with the putative role of FLI as early predictor of MetS and likely reflects that the main site of
expression of FMO3, the enzyme that metabolizes gut microbe-derived TMA to produce TMAO, is the
liver. Based on ROC curve analysis, the most sensitive and specific cut-offs for circulating levels of
TMAO to predict the presence of NAFLD-FLI and MetS were ≥8.02 µM and ≥8.74 µM, respectively.
Experimental studies in mice fed with a high-fat diet showed that a high urinary excretion of TMAO
was associated with insulin resistance and NAFLD in mice (129S6) prone to these diseases [44].
Miao et al. [45] found that liver insulin receptor knockout mice, characterized by a selective hepatic
insulin resistance, have increased circulating TMAO levels associated with a strong up-regulation of the
TMAO-producing enzyme FMO3 in the liver [45]. According to the proposed mechanism, TMAO may
block the hepatic insulin signaling pathway, thereby exacerbating the impaired glucose tolerance, and
promoting the development of fatty liver [46]. Turning to human studies, the above-mentioned study
by Randrianarisoa et al. [12] reported a positive correlation between TMAO and liver fat content [12].
In addition, in a large sample of hospital and community-based Chinese adults, Chen et al. [13] showed
positive associations of the circulating TMAO levels and two of its nutrient precursors, choline and
betaine, with the presence and severity of NAFLD [13]. Choline can be oxidized to betaine, and
betaine is generally regarded as safe for dietary ingestion due to its sparing effects on choline, a basic
component for the synthesis of phosphatidylcholine, which in turn is necessary for promoting lipid
exportation from the liver [47]. In this study, the authors suggested that TMAO may represent a
possible risk factor for NAFLD due to its effect in altering the synthesis and transport of bile acids, with
subsequent effects on lipid metabolism, intrahepatic triglycerides levels and glucose homeostasis [6].
More recently, Ntzouvani et al. [18] reported a strong positive association between liver function and a
pattern of amino acids, which included TMAO, in a sample of Greek adult males with MetS [18].
The results of this study lend support to the evidence that circulating levels of TMAO were
positively associated with body weight, thus concurring with an increased risk of developing MetS,
through insulin resistance, adipocyte dysfunction, and fatty liver. In this context, it is tempting to
hypothesize that circulating levels of TMAO could have a role of a biological marker of early metabolic
derangement in subjects with overweight and obesity. Thus, it allows speculation on the possible
beneficial and cost-effective effects to early address specific nutrition interventions aimed to reduce
the excessive intake of TMAO precursors in subjects at risk of MetS and NAFLD.
Despite these very interesting results, the main limitation of this study is that the cross-sectional
design does not allow identification of any causal association between the variables included. Thus,
it is not possible to clearly determine the prognostic value of circulating levels of TMAO for predicting
the early metabolic derangement in subjects with overweight and obesity. Second, although it is
well known that the gut-derived origin of TMAO and dietary intake are important determinants of
TMAO levels, we did not include in this study the gut microbiota and single-nutrient analysis. In
particular, Kühn et al. [48] reported also that both dietary habits and the composition of the intestinal
microbiota may be prone to changes, despite a certain stability of both factors during adulthood. On
the other hand, Krüger et al. [49] reported that the large inter-individual variations TMAO levels
have been mainly attributed to intestinal microbiota differences, while the influence of diet on fasting
TMAO concentrations, albeit statistically significant, could be considered rather moderate. However,
there is a large consensus that the study of gut microbiota is burdened by a high intra-individual
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variability that might hinder the interpretation of the results [48,50–52]. Third, we did not include the
evaluation of markers of inflammation, such as C-reactive protein, or metabolic precursor of TMAO
such as choline, betaine or carnitine, and liver expression of FMO3. However, several studies have
shown that the associations between plasma TMAO and disease outcomes were independent of TMAO
precursors [53–55]. In addition, the adverse effects of FMO3 on metabolic disease may be driven by
factors other than TMAO, and the expression of the FMO3 or markers of inflammation encompassed
the design of the present study. Fourth, we are aware that the liver biopsy is the gold-standard
technique for identifying NAFLD. Liver biopsy is an invasive and costly procedure burdened with
rare but potentially life-threatening complications. On the contrary, FLI has proved to represent an
easy screening tool to identify NAFLD in patients with cardio-metabolic risk factors where ultrasound
is unavailable [21,56,57], which is associated with reduced insulin sensitivity, and increased risk of
T2DM, atherosclerosis, and cardiovascular disease [43]. Nevertheless, a major strength of this study is
the good characterization of our sample population across BMI classes, with the exclusion of impaired
renal function and T2DM known factors that can affect TMA metabolism, and likely with similar
nutrient availability and food consumption pattern, as they were living in the same geographical
area. Furthermore, we included of a variety of potential covariates, such as the total energy intake, to
minimize the effect of confounding factors on the association of TMAO with adiposity. However, since
complete understanding of TMAO biology is still lacking, the potential translation application of the
results of this study to the clinical practice requires large-scale data investigating the beneficial and
cost-effective effects of specific nutrition intervention aimed to avoid the excessive intake of TMAO
precursors in subjects at risk of MetS and NAFLD. The main results of our study, compared to the
results of the general literature, is reported in Table 6.
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Table 6. A summary table with the main results of our study compared to the results of the general literature.
Parameters Methodology Participants Effects Hypothesis Studies Concordance
Nascent Metabolic
Syndrome
(MetS)
Case-control clinical
study 30 patients20 controls TMAO with a trend of positive correlation
TMAO levels rise only
after MetS has advanced to the later
stages including T2DM and/or CVD
[9] Yes
HoMA-IR Case-control clinicalstudy
30 patients
20 controls TMAO not significantly correlated
No major role for TMAO
in glucose metabolism or insulin
sensitivity
[9] No
Intervention Program 220 subjects A negative correlation between circulatingTMAO levels insulin sensitivity
In obese, hyperglycemic humans FMO3
expression and TMAO levels are
increased in hepatic insulin resistance.
[12] Yes
NAFLD Experimental study
Mouse strain 129S6,
documented for its
susceptibility to IR or NAFLD
Mice 129S6 fed with a high-fat diet showed a
high urinary excretion of TMAO associated
with insulin resistance and NAFLD
A high-fat diet reduces the conversion
and the bioavailability of choline by
microbiota, causing NAFLD
[44] Yes
Experimental study
Male ob/ob mice and their
lean, wild-type C57BL/6J
controls
Liver insulin receptor knockout mice with
selective hepatic insulin resistance have
increased circulating TMAO levels associated
with a strong up-regulation of the
TMAO-producing enzyme FMO3 in the liver
TMAO may block the hepatic insulin
signaling pathway promoting the
development of fatty liver
[11] Yes
Case-control study
(CCS) and
cross-sectional study
(CSS)
60 adult patients and 35
controls for CCS
1.628participants for CSS
TMAO is an independent risk marker for
NAFLD in humans. in both the CCS and CSS
studies
TMAO decreases the total bile acid pool
size and influences the hepatic
triglycerides levels, as a potential risk
factor for fatty liver disease
[13] Yes
Intervention Program 220 subjects A positive correlation between circulatingTMAO levels and liver fat content
Fasting levels of TMAO are regulated by
hepatic FMO3 [12] Yes
Cross-sectional study One hundred middle-agedmen
A strong positive association between liver
function and a pattern of amino acids, which
included TMAO
A pattern of amino acids, included
TMAO, are regulated by liver enzymes [18] Yes
Abbreviations: MetS, Metabolic Syndrome; TMAO, Trimethylamine N-oxide; T2DM, Type 2 Diabetes Mellitus; CVD, Cardiovascular Diseases; HoMA-IR, Homeostatic Model Assessment
Insulin Resistance; FMO3, Flavin-containing Monooxygenases; NAFLD, non-alcoholic fatty liver disease; IR, insulin Resistance; CCS, Case-control Study; CSS, Cross-sectional Study.
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5. Conclusions
In conclusion, this study in a sample of adult subjects stratified according to their BMI: (i) reported
a positive association between adiposity and circulating levels of TMAO; (ii) confirmed the positive
association between circulating levels of TMAO and MetS; and (iii) further expanded the knowledge
of the relationship of TMAO and MetS, as we reported novel associations between circulating levels
of TMAO and two early indicators of MetS. In particular, in this study we demonstrated that FLI is
more tightly associated with TMAO levels than the presence of MetS per se. These associations let us
to hypothesize a role of TMAO as an early biomarker of NAFLD-FLI in all borderline conditions in
which overt MetS is not present. Moreover, given the current performance of therapies for MetS, we
suggest that a specific cut-off of TMAO might help in identifying subjects at high risk of NAFLD, who
will require specific nutrition intervention strategies. Appropriate cross-validation studies in larger
patient population samples are mandatory to validate the cut-off of TMAO for the identification of
subjects at high risk of NAFLD-FLI.
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HoMA-IR Homeostatic Model Assessment of Insulin Resistance
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FLI Fatty Liver Index
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